The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

CHEMBL1593     3-[amino-[bis(2- chloroethyl)amino]phosphor...

Synonyms: AG-F-21072, AC1Q6SYU, CTK1C3648, AR-1F4851, AC1L32O7, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C07645


High impact information on C07645


Biological context of C07645


Anatomical context of C07645


Associations of C07645 with other chemical compounds


Gene context of C07645


Analytical, diagnostic and therapeutic context of C07645


  1. 31P nuclear magnetic resonance spectroscopic observation of the intracellular transformations of oncostatic cyclophosphamide metabolites. Boyd, V.L., Robbins, J.D., Egan, W., Ludeman, S.M. J. Med. Chem. (1986) [Pubmed]
  2. Effect of stereochemistry on the oxidative metabolism of the cyclophosphamide metabolite aldophosphamide. Habib, A.D., Boal, J.H., Hilton, J., Nguyen, T., Chang, Y.H., Ludeman, S.M. Biochem. Pharmacol. (1995) [Pubmed]
  3. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine. Maki, P.A., Sladek, N.E. Cancer Res. (1991) [Pubmed]
  4. Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: a strategy for tumor-selective activation of cytocidal drugs. Tietze, L.F., Neumann, M., Möllers, T., Fischer, R., Glüsenkamp, K.H., Rajewsky, M.F., Jähde, E. Cancer Res. (1989) [Pubmed]
  5. The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in vitro: implications for use in bone marrow purging. Beran, M., Andersson, B.S., Wang, Y., McCredie, K.B., Farquhar, D. Cancer Res. (1988) [Pubmed]
  6. Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. Bunting, K.D., Townsend, A.J. J. Biol. Chem. (1996) [Pubmed]
  7. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Anderson, L.W., Chen, T.L., Colvin, O.M., Grochow, L.B., Collins, J.M., Kennedy, M.J., Strong, J.M. Clin. Cancer Res. (1996) [Pubmed]
  8. Coding region-specific destabilization of mRNA transcripts attenuates expression from retroviral vectors containing class 1 aldehyde dehydrogenase cDNAs. Bunting, K.D., Webb, M., Giorgianni, F., Galipeau, J., Blakley, R.L., Townsend, A.J., Sorrentino, B.P. Hum. Gene Ther. (1997) [Pubmed]
  9. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Dockham, P.A., Lee, M.O., Sladek, N.E. Biochem. Pharmacol. (1992) [Pubmed]
  10. Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. Tsukamoto, N., Chen, J., Yoshida, A. Blood Cells Mol. Dis. (1998) [Pubmed]
  11. Direct detection of the intracellular formation of carboxyphosphamides using nuclear magnetic resonance spectroscopy. Boal, J.H., Ludeman, S.M., Ho, C.K., Engel, J., Niemeyer, U. Arzneimittel-Forschung. (1994) [Pubmed]
  12. Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines. Dockham, P.A., Sreerama, L., Sladek, N.E. Drug Metab. Dispos. (1997) [Pubmed]
  13. Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies. Sonawat, H.M., Leibfritz, D., Engel, J., Hilgard, P. Biochim. Biophys. Acta (1990) [Pubmed]
  14. Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase. Bunting, K.D., Lindahl, R., Townsend, A.J. J. Biol. Chem. (1994) [Pubmed]
  15. Effects of N-substitution on the activation mechanisms of 4-hydroxycyclophosphamide analogues. Kwon, C.H., Borch, R.F. J. Med. Chem. (1989) [Pubmed]
  16. Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3. Giorgianni, F., Bridson, P.K., Sorrentino, B.P., Pohl, J., Blakley, R.L. Biochem. Pharmacol. (2000) [Pubmed]
  17. Kinetic characterization of the catalysis of "activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases. Manthey, C.L., Sladek, N.E. Biochem. Pharmacol. (1988) [Pubmed]
  18. NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide. Parekh, H.K., Sladek, N.E. Biochem. Pharmacol. (1993) [Pubmed]
  19. Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis. Belfayol-Pisanté, L., Guillevin, L., Tod, M., Fauvelle, F. Fundamental & clinical pharmacology. (2000) [Pubmed]
WikiGenes - Universities